Anika Therapeutics, Inc. Revenue
Anika Therapeutics, Inc. (ANIK) reported Revenue of $32.61 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-07-29.
Financial Statements › Income Statement
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax · last filed 2026-07-29
- Anika Therapeutics, Inc. revenue from contract with customer, excluding assessed tax for the quarter ending 2026-06-30 was $32.61M, a 15.56% increase year-over-year.
- Anika Therapeutics, Inc. revenue from contract with customer, excluding assessed tax for the quarter ending 2026-03-31 was $29.61M, a 13.16% increase year-over-year.
- Anika Therapeutics, Inc. revenue from contract with customer, excluding assessed tax for the quarter ending 2025-12-31 was $30.61M, a 0.04% increase year-over-year.
- Anika Therapeutics, Inc. revenue from contract with customer, excluding assessed tax for the quarter ending 2025-09-30 was $27.82M, a 5.89% decline year-over-year.
- Anika Therapeutics, Inc. revenue from contract with customer, excluding assessed tax for fiscal 2025 was $112.82M, a 5.91% decline from fiscal 2024.
- Anika Therapeutics, Inc. revenue from contract with customer, excluding assessed tax for fiscal 2024 was $119.91M, a 0.73% decline from fiscal 2023.
- Anika Therapeutics, Inc. revenue from contract with customer, excluding assessed tax for fiscal 2023 was $120.79M, a 6.12% increase from fiscal 2022.
- Anika Therapeutics, Inc. revenue from contract with customer, excluding assessed tax for fiscal 2022 was $113.83M, a 22.98% decline from fiscal 2021.
| Period end | Revenue from Contract with Customer, Excluding Assessed Tax 3 month | Revenue from Contract with Customer, Excluding Assessed Tax 3 month as first filed | Revenue from Contract with Customer, Excluding Assessed Tax 6 month | Revenue from Contract with Customer, Excluding Assessed Tax 6 month as first filed | Revenue from Contract with Customer, Excluding Assessed Tax 9 month | Revenue from Contract with Customer, Excluding Assessed Tax 9 month as first filed | Revenue from Contract with Customer, Excluding Assessed Tax 12 month | Revenue from Contract with Customer, Excluding Assessed Tax 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $32.61M 10-Q · filed 2026-07-29 | $62.22M 10-Q · filed 2026-07-29 | $92.84M derived: sum of 3 quarters · filed 2026-07-29 | $120.65M derived: sum of 4 quarters · filed 2026-07-29 | ||||
| 2026-03-31 | $29.61M 10-Q · filed 2026-04-30 | $60.23M derived: sum of 2 quarters · filed 2026-04-30 | $88.04M derived: sum of 3 quarters · filed 2026-04-30 | $116.26M derived: sum of 4 quarters · filed 2026-07-29 | ||||
| 2025-12-31 | $30.61M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-03 | $58.43M derived: sum of 2 quarters · filed 2026-03-03 | $86.65M derived: sum of 3 quarters · filed 2026-07-29 | $112.82M 10-K · filed 2026-03-03 | ||||
| 2025-09-30 | $27.82M 10-Q · filed 2025-11-05 | $56.04M derived: sum of 2 quarters · filed 2026-07-29 | $82.20M 10-Q · filed 2025-11-05 | $112.81M derived: sum of 4 quarters · filed 2026-07-29 | ||||
| 2025-06-30 | $28.22M 10-Q · filed 2026-07-29 | $54.39M 10-Q · filed 2026-07-29 | $84.99M derived: sum of 3 quarters · filed 2026-07-29 | $114.55M derived: sum of 4 quarters · filed 2026-07-29 | ||||
| 2025-03-31 | $26.17M 10-Q · filed 2026-04-30 | $56.77M derived: sum of 2 quarters · filed 2026-04-30 | $86.33M derived: sum of 3 quarters · filed 2026-04-30 | $117.05M derived: sum of 4 quarters · filed 2026-04-30 | ||||
| 2024-12-31 | $30.60M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-03 | $60.16M derived: sum of 2 quarters · filed 2026-03-03 | $90.89M derived: sum of 3 quarters · filed 2026-03-03 | $119.91M 10-K · filed 2026-03-03 | ||||
| 2024-09-30 | $29.56M 10-Q · filed 2025-11-05 | $38.75M 10-Q · filed 2024-11-04 | $60.28M derived: sum of 2 quarters · filed 2025-11-05 | $89.31M 10-Q · filed 2025-11-05 | $121.20M 10-Q · filed 2024-11-04 | $86.41M derived: sum of 4 quarters · filed 2026-03-03 | ||
| 2024-06-30 | $30.72M 10-Q · filed 2025-07-30 | $41.92M 10-Q · filed 2024-08-08 | $59.75M 10-Q · filed 2025-07-30 | $82.44M 10-Q · filed 2024-08-08 | $56.85M derived: sum of 3 quarters · filed 2026-03-03 | $98.31M derived: sum of 4 quarters · filed 2026-03-03 | ||
| 2024-03-31 | $29.02M 10-Q · filed 2025-05-09 | $40.52M 10-Q · filed 2024-05-08 | $26.12M derived: sum of 2 quarters · filed 2026-03-03 | $67.59M derived: sum of 3 quarters · filed 2026-03-03 | $111.89M derived: sum of 4 quarters · filed 2026-03-03 | |||
| 2023-12-31 | -$2.90M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-03 | $38.57M derived: sum of 2 quarters · filed 2026-03-03 | $82.87M derived: sum of 3 quarters · filed 2026-03-03 | $120.79M 10-K · filed 2026-03-03 | $166.66M 10-K · filed 2024-03-15 | |||
| 2023-09-30 | $41.47M 10-Q · filed 2024-11-04 | $85.77M derived: sum of 2 quarters · filed 2024-11-04 | $123.69M 10-Q · filed 2024-11-04 | $120.90M derived: sum of 4 quarters · filed 2025-03-17 | ||||
| 2023-06-30 | $44.30M 10-Q · filed 2024-08-08 | $82.23M 10-Q · filed 2024-08-08 | $79.44M derived: sum of 3 quarters · filed 2025-03-17 | $119.70M derived: sum of 4 quarters · filed 2025-03-17 | ||||
| 2023-03-31 | $37.92M 10-Q · filed 2024-05-08 | $35.14M derived: sum of 2 quarters · filed 2025-03-17 | $75.40M derived: sum of 3 quarters · filed 2025-03-17 | $115.06M derived: sum of 4 quarters · filed 2025-03-17 | ||||
| 2022-12-31 | -$2.79M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-17 | $37.48M derived: sum of 2 quarters · filed 2025-03-17 | $77.13M derived: sum of 3 quarters · filed 2025-03-17 | $113.83M 10-K · filed 2025-03-17 | $156.24M 10-K · filed 2023-03-16 | |||
| 2022-09-30 | $40.26M 10-Q · filed 2023-11-03 | $79.92M derived: sum of 2 quarters · filed 2023-11-03 | $116.61M 10-Q · filed 2023-11-03 | $152.44M derived: sum of 4 quarters · filed 2024-03-15 | ||||
| 2022-06-30 | $39.66M 10-Q · filed 2023-08-08 | $76.35M 10-Q · filed 2023-08-08 | $112.17M derived: sum of 3 quarters · filed 2024-03-15 | $151.71M derived: sum of 4 quarters · filed 2024-03-15 | ||||
| 2022-03-31 | $36.69M 10-Q · filed 2023-05-09 | $72.51M derived: sum of 2 quarters · filed 2024-03-15 | $112.05M derived: sum of 3 quarters · filed 2024-03-15 | $150.19M derived: sum of 4 quarters · filed 2024-03-15 | ||||
| 2021-12-31 | $35.82M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-15 | $75.36M derived: sum of 2 quarters · filed 2024-03-15 | $113.50M derived: sum of 3 quarters · filed 2024-03-15 | $147.79M 10-K · filed 2024-03-15 | ||||
| 2021-09-30 | $39.54M 10-Q · filed 2022-11-09 | $39.54M 10-Q · filed 2022-11-09 | $111.97M 10-Q · filed 2022-11-09 | $144.66M derived: sum of 4 quarters · filed 2022-11-09 | ||||
| 2021-06-30 | $38.15M 10-Q · filed 2022-08-04 | $72.44M 10-Q · filed 2022-08-04 | $105.13M derived: sum of 3 quarters · filed 2022-08-04 | $136.82M derived: sum of 4 quarters · filed 2022-08-04 | ||||
| 2021-03-31 | $34.29M 10-Q · filed 2022-05-06 | $66.98M derived: sum of 2 quarters · filed 2022-05-06 | $98.67M derived: sum of 3 quarters · filed 2022-05-06 | $129.35M derived: sum of 4 quarters · filed 2022-05-06 | ||||
| 2020-12-31 | $32.69M 10-K/A · filed 2021-04-26 | $64.38M derived: sum of 2 quarters · filed 2021-11-05 | $95.06M derived: sum of 3 quarters · filed 2021-11-05 | $130.46M 10-K · filed 2023-03-16 | ||||
| 2020-09-30 | $31.69M 10-Q · filed 2021-11-05 | $62.37M derived: sum of 2 quarters · filed 2021-11-05 | $97.77M 10-Q · filed 2021-11-05 | $127.54M derived: sum of 4 quarters · filed 2021-11-05 | ||||
| 2020-06-30 | $30.68M 10-Q · filed 2021-08-06 | $66.08M 10-Q · filed 2021-08-06 | $95.85M derived: sum of 3 quarters · filed 2021-08-06 | $125.54M derived: sum of 4 quarters · filed 2021-08-06 | ||||
| 2020-03-31 | $35.40M 10-Q · filed 2021-05-07 | $65.17M derived: sum of 2 quarters · filed 2021-05-07 | $94.87M derived: sum of 3 quarters · filed 2021-05-07 | $125.28M derived: sum of 4 quarters · filed 2021-05-07 | ||||
| 2019-12-31 | $29.77M 10-K/A · filed 2021-04-26 | $59.47M derived: sum of 2 quarters · filed 2021-04-26 | $89.89M derived: sum of 3 quarters · filed 2021-04-26 | $114.61M 10-K · filed 2022-03-11 | ||||
| 2019-09-30 | $29.70M 10-K/A · filed 2021-04-26 | $60.12M derived: sum of 2 quarters · filed 2021-04-26 | $84.84M 10-Q · filed 2020-11-05 | $111.79M derived: sum of 4 quarters · filed 2021-04-26 | ||||
| 2019-06-30 | $30.42M 10-K/A · filed 2021-04-26 | $55.14M 10-Q · filed 2020-08-07 | $82.10M derived: sum of 3 quarters · filed 2021-04-26 | $108.88M derived: sum of 4 quarters · filed 2021-04-26 | ||||
| 2019-03-31 | $24.72M 10-K/A · filed 2021-04-26 | $51.68M derived: sum of 2 quarters · filed 2021-04-26 | $78.47M derived: sum of 3 quarters · filed 2021-04-26 | $109.01M derived: sum of 4 quarters · filed 2021-04-26 | ||||
| 2018-12-31 | $26.96M 10-K · filed 2020-03-06 | $53.74M derived: sum of 2 quarters · filed 2020-03-06 | $84.29M derived: sum of 3 quarters · filed 2020-03-06 | $105.56M 10-K/A · filed 2021-04-26 | ||||
| 2018-09-30 | $26.79M 10-K · filed 2020-03-06 | $57.34M derived: sum of 2 quarters · filed 2020-03-06 | $78.60M 10-Q · filed 2019-10-28 | $107.99M derived: sum of 4 quarters · filed 2020-03-06 | ||||
| 2018-06-30 | $30.55M 10-K · filed 2020-03-06 | $51.81M 10-Q · filed 2019-07-26 | $81.20M derived: sum of 3 quarters · filed 2020-03-06 | $108.38M derived: sum of 4 quarters · filed 2020-03-06 | ||||
| 2018-03-31 | $21.26M 10-K · filed 2020-03-06 | $50.65M derived: sum of 2 quarters · filed 2020-03-06 | $77.84M derived: sum of 3 quarters · filed 2020-03-06 | $111.30M derived: sum of 4 quarters · filed 2020-03-06 | ||||
| 2017-12-31 | $29.39M 10-K · filed 2019-02-27 | $56.57M derived: sum of 2 quarters · filed 2019-02-27 | $90.03M derived: sum of 3 quarters · filed 2019-02-27 | $113.42M 10-K · filed 2020-03-06 | ||||
| 2017-09-30 | $27.18M 10-K · filed 2019-02-27 | $60.65M derived: sum of 2 quarters · filed 2019-02-27 | $84.03M derived: sum of 3 quarters · filed 2019-02-27 | |||||
| 2017-06-30 | $33.46M 10-K · filed 2019-02-27 | $56.85M derived: sum of 2 quarters · filed 2019-02-27 | ||||||
| 2017-03-31 | $23.39M 10-K · filed 2019-02-27 | |||||||
| 2016-12-31 | $103.38M 10-K · filed 2019-02-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ORASURE TECHNOLOGIES INC (OSUR) | United States | $0.272B | -6.26 |
| Cytosorbents Corp (CTSO) | United States | $0.274B | -1.29 |
| TriSalus Life Sciences, Inc. (TLSI) | United States | $0.283B | -9.92 |
| InfuSystem Holdings, Inc (INFU) | United States | $0.253B | 22.52 |
| Mobia Medical, Inc. (MOBI) | United States | $0.293B | |
| TREACE MEDICAL CONCEPTS, INC. (TMCI) | United States | $0.297B | -4.32 |
| UTAH MEDICAL PRODUCTS INC (UTMD) | United States | $0.238B | 20.93 |
| PRO DEX INC (PDEX) | United States | $0.234B | 13.64 |
| Embecta Corp. (EMBC) | United States | $0.319B | 2.10 |
| Neuronetics, Inc. (STIM) | United States | $0.216B | -3.25 |